Stocks · News reference
Disc Medicine Reports Q3 2026 Financial Results and Operational Progress
Disc Medicine announced its third-quarter 2026 financial results, highlighting the success of the APOLLO trial and a planned NDA resubmission for bitopertin by the end of the year.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Initiates Coverage of Disc Medicine with Buy Rating
Guggenheim Securities has initiated coverage of Disc Medicine, Inc. with a Buy rating and a price target of $132.
Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate
8-K filing — Disc Medicine, Inc. (IRON)
Filed: 2026-11-05 AccNo: 0001193125-26-448711 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Premier Miton Group plc Reduces Holding in Ironveld PLC
Premier Miton Group plc has decreased its stake in Ironveld PLC to below 5% following a disposal of voting rights.
Disc Medicine Announces Multiple Presentations at the 68th ASH Annual Meeting
Disc Medicine will present additional data from its Phase 2 clinical trials for selcodebart (DISC-0974) and DISC-3405 at the upcoming 68th American Society of Hematology (ASH) Annual Meeting.